Using luciferase reporter, gene knockdown, and functional assays, they determined that GATA3 transcriptionally activates KLHL42 in SS, and its silencing promotes apoptosis and inhibits rapid CTCL proliferation, making KLHL42 a promising but currently unutilized therapeutic target [53]. This evidence concerns the gene GATA3 and synovial sarcoma.